D e s i g n
Randomized (allocation concealed*), unblinded,* controlled trial with 6-month follow-up.
S e t t i n g
{14 university and nonuniversity hospitals} † in Switzerland. P a t i e n t s 305 patients who were ≥ 75 years of age (mean age 80 y, 56% men) with at least CCS class-II angina pectoris despite treatment with ≥ 2 antianginal drugs. Exclusion criteria included acute myocardial infarction (MI) within the previous 10 days, concomitant valvular or other heart disease, predominant congestive heart failure, and life-limiting comorbid disease. 4 patients (2 from each group) were not included in the analysis.
I n t e r v e n t i o n 155 patients were allocated to an invasive strategy consisting of coronary angiography followed by PCI or CABG if feasible. 150 patients were allocated to optimizing medical therapy consisting of an increase in the number or dose of antianginal drugs.
M a i n o u t c o m e m e a s u r e s
The primary end points were quality of life and major adverse cardiac events (death, nonfatal MI, or hospitalization for an acute coronary syndrome).
M a i n r e s u l t s
Analysis was by intention to treat. At 6 months, quality of life increased in both treatment groups, but data for the paired analysis were available for < 80% of those randomized. Angina severity and number of anginal medications taken decreased to a greater extent, and major adverse cardiac events occurred less frequently in those allocated to the invasive strategy (Table) .
C o n c l u s i o n
Revascularization led to less angina and fewer major adverse cardiac events than did optimal medical care in patients ≥ 75 years of age with at least class-II angina pectoris despite treatment with ≥ 2 antianginal drugs. 
C o m m e n t a r y
The advantage of direct or catheter-based revascularization over medical treatment in the general population with advanced forms of coronary disease is well documented (1) . The TIME trial sought to determine whether these results could be reliably applied to elderly patients when the risk associated with intervention is greater. The design of the study allowed considerable latitude to determine which strategy would be used in the invasive group. This latitude probably accurately reflects common treatment scenarios in many centers. Several important points, however, should be noted. A bias against surgery is suggested by the small number of patients assigned surgery (33 of 147 patients) despite 88 having 3-vessel disease and 21 having leftmain disease. Furthermore, the "intensification" of care in the 150 patients assigned to optimal medical treatment resulted in the addition of < 1 (0.8) antianginal medication per patient, and only about half (55%) of the patients had additional increases in drug dosages.
Notwithstanding possible bias against surgery and the limited opportunity for medication optimization, the invasive group fared much better at 6 months. Event-free survival in these patients was higher in the invasive group (81%) than the medical group (51%) (P < 0.001). This information is useful for those treating the elderly, and it parallels the 22% relative risk reduction in a younger group of patients reported in the Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease (FRISC II) trial (2) . These data support early angiography and invasive treatment in stable elderly patients with class-II or greater angina. Major adverse cardiac 19% 49% 61% (44 to 73) 4 (3 to 6) events ‡Abbreviations defined in Glossary; RRR, NNT, and CI calculated from data in article.
